From a CRISPR therapy's FDA priority review to oral HAE prophylaxis data and a needle-free epinephrine resubmission, 4 allergy stories from September.

Florence Schleich, MD, PhD, explains how exacerbation phenotypes and useful biomarkers shift across anti-IL-5, anti-IL-5R, and anti-TSLP therapies.

DBV has requested priority review for the epicutaneous patch, supported by phase 3 VITESSE data showing a 31.8-point responder rate gain vs placebo.

Remibrutinib doubled complete Total Fric Score response vs placebo at week 12 in RemIND, becoming the first therapy approved specifically for SD.

Physicians and patients cited perceived mild severity as the top reason for leaving HAE attacks untreated in a recent Adelphi survey.

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.

Ryaltris pediatric approval, lonvo-z and deucrictibant HAE filings, PVX108 Fast Track, and Palforzia's exit headline Q3 2026 allergy news.

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.